Retatrutide vs Cagrilintide — Triple Agonist vs Amylin+GLP-1
Retatrutide is an investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly in Phase 2/3 trials. Cagrilintide is an investigational long-acting amylin analog from Novo Nordisk, studied both alone and in combination with semaglutide (CagriSema). Both are investigational — neither is FDA-approved or available outside clinical trial settings.
Mechanism Comparison
| Property | Retatrutide (LY3437943) | Cagrilintide (AMY611) |
|---|---|---|
| Receptor targets | GIP + GLP-1 + Glucagon (triple agonist) | Amylin receptor (long-acting amylin analog) |
| Development phase | Phase 2/3 (Eli Lilly) | Phase 3 with semaglutide as CagriSema (Novo Nordisk) |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Combination studied | Standalone triple agonist | Combined with semaglutide (CagriSema) |
| Legal availability | Clinical trial only | Clinical trial only |
| Key distinction | Three hormone pathways, single molecule | Amylin pathway, typically combined with GLP-1 |
Evidence Maturity
| Dimension | Retatrutide (LY3437943) | Cagrilintide (AMY611) |
|---|---|---|
| Clinical trial data | TRIUMPH-1 (Phase 2) published; Phase 3 ongoing | Phase 2 data published; Phase 3 for CagriSema ongoing |
| Published weight-loss results | Substantial early results (triple agonism) | Promising — amylin + GLP-1 combination effect |
| Safety characterization | Early stage — GI effects being characterized | Better established — amylin class has prior experience |
Regulatory Status
Neither retatrutide nor cagrilintide is FDA-approved. Both are investigational compounds in active clinical trial programs. Products from research vendors claiming to be either compound cannot be verified as genuine, as no reference standards are available to independent laboratories. The FDA has warned against unapproved GLP-1 and related drugs used for weight loss.
Quality and COA Checklist
- Third-party COA: Both compounds should have batch-linked certificates from independent laboratories
- Purity ≥98%: HPLC/MS data should be visible — not just a stated percentage
- Research-use-only labeling: Vendors should not provide dosing, injection, or human-use guidance
- Transparent payment: Legitimate vendors have clear business payment methods and refund policies
- Source dating: COAs should be within the last 6–12 months for current inventory
Frequently Asked Questions
Are retatrutide or cagrilintide available by prescription?
No. Both are investigational compounds in clinical trials. Neither has received FDA approval for any indication.
What is the main difference between them?
Retatrutide is a single molecule targeting three hormone receptors (GIP, GLP-1, glucagon). Cagrilintide is a long-acting amylin analog typically studied in combination with semaglutide — a different pharmacological approach using two different molecules.
Can I buy these from research vendors?
Products claiming to be retatrutide or cagrilintide from research vendors cannot be verified. As investigational compounds, there are no reference standards available to independent testing labs. This makes authentication impossible.
When might these become available?
Timelines depend on trial outcomes and regulatory review. Neither has a confirmed approval date. Follow ClinicalTrials.gov and FDA announcements for official updates.
Is CagriSema the same as cagrilintide?
CagriSema is the combination of cagrilintide (amylin analog) plus semaglutide (GLP-1 agonist) developed by Novo Nordisk. Cagrilintide is the amylin component — CagriSema is the combination product name.
Related Pages
Peptide Vendor Rankings → · How to Read a COA → · Our Evaluation Methodology →
Verification Notes for Retatrutide vs Cagrilintide — Triple Agonist vs Amylin+GLP-1
This file is reviewed as part of the The Peptide Reviewer documentation system, which means the page is not judged by headline confidence alone. The desk checks whether the claim has a date, whether the source can be opened by a reader, whether commercial language is separated from editorial scoring, and whether a medical or regulatory boundary is visible before the reader reaches any vendor context.
For retatrutide vs cagrilintide, the practical standard is source literacy. A reader should be able to trace the page back to primary records, compare those records with the current vendor or compound claim, and see what the page does not prove. If a vendor changes a COA, removes a lab report, edits a product page, or adds health-outcome language after this review date, the conclusion can change. That is why this publication keeps source dates, correction rules, and reviewer scope close to the article body instead of hiding them in a footer.
The editorial team uses the same baseline checks across peptide vendor reviews, compound explainers, comparison pages, trust pages, and author pages. First, the page must identify the entity or topic clearly. Second, it must point readers toward primary-source verification. Third, it must avoid personal-use instructions and medical recommendations. Fourth, it must disclose when affiliate economics could exist and state that payment does not change scoring, inclusion, risk labels, or rank order.
When the page discusses a compound, the review separates published research context from research-market product claims. Published studies, trial records, or regulatory documents can describe a molecule, but they do not verify a private vendor batch. When the page discusses a vendor, the review separates a vendor's public marketing from documentation that can be checked, including batch-linked certificates, lab identity, source dates, claims language, and correction history.
Readers should treat this file as an audit trail, not a shortcut. The safest way to use it is to open the listed sources, confirm the current date on the vendor or regulatory record, and compare that source with the page summary. If the source and summary disagree, the source wins until the page is corrected. If the source cannot be found, the claim should be treated as unverified.
This added review note also gives crawlers and readers the same context that the editors use internally: what kind of evidence matters, which trust pages govern the file, who owns the review boundary, and where a correction should start. That matters most on author, policy, and directory pages because those pages can look thin even when they carry important E-E-A-T signals. The added context makes the page auditable without turning it into a new article.
- PubMed for published biomedical literature and review context.
- ClinicalTrials.gov for registered trial status and study records.
- FDA for approval status, warning letters, labeling, and regulatory context.
Frequently Asked Questions
How should I verify this page?
Start with the date, then open the primary source rather than relying on a summary. For medical or regulatory context, check PubMed, ClinicalTrials.gov, and FDA records. For vendor context, check the live vendor page, the batch-linked COA, the named lab, and any archived claim record.
Does this page provide medical advice?
No. The Peptide Reviewer publishes editorial source checks and market-transparency reviews. It does not provide treatment advice, dosing protocols, cycles, stacks, injection instructions, reconstitution guidance, diagnosis help, or personal-use recommendations.
Can affiliate relationships change the conclusion?
No. Affiliate relationships, sponsored links, and referral economics do not change scoring, inclusion, rank position, risk labels, author attribution, or medical-review status. Any paid link must be disclosed before the link and marked with sponsored nofollow attributes.
What happens if a source changes?
The page should be updated through the corrections process. A new COA, a changed vendor claim, an FDA update, or a corrected trial record can change the page. Until that update is made, readers should trust the current primary source over the older summary.
Related Standards
Methodology → · Editorial Standards → · Medical Review Policy → · Corrections Policy → · Affiliate Disclosure →